Author:
Fesler Mark J.,Nguyen Nghi C.,Petruska Paul J.
Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Barlett N. Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematology Am Soc Hematol Educ Program. 2005;1:246.
2. Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. Ann Oncol. 1997;8(2):143–8.
3. Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–54.
4. Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, et al. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma. 2009;50(11):1803–8.
5. Eichenauer DA, Engert A. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma? Leuk Lymphoma. 2009;50(11):1733–4.